Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Norming U, Nyman CR, Tribukait B. Comparative histopathology and deoxyribonucleic acid flow cytometry of random mucosal biopsies in untreated bladder carcinoma. J Urol 1991;145:1164–8.
   PubMed Web of Science ®Google Scholar
• Wolf H, Rosenkilde Olsen P, Fischer A, Højgaard K. Urothelial atypia concomitant with primary bladder tumour. Incidence in a consecutive series of 500 unselected patients. Scand J Urol Nephrol 1987;21:33–8.
   PubMed Web of Science ®Google Scholar
• Lamm D. Carcinoma in situ. Urol Clin North Am 1992;19:499–508.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Hagberg O, Holmäng S, Hosseini Aliabad A, Jancke G, Ljungberg B, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol 2015;49:290–5.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639–53.
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Nordic Urothelial Cancer Group, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003;43:637–45.
   PubMed Web of Science ®Google Scholar
• Hemdan T, Johansson R, Jahnson S, Hellström P, Tasdemir I, Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014;191:1244–9.
   PubMed Web of Science ®Google Scholar
• Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) in more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol 2015;67:508–16.
   PubMed Web of Science ®Google Scholar
• Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH, et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 2010;184:74–80.
   PubMed Web of Science ®Google Scholar
• Chade DC, Shariat SF, Adamy A, Bochner BH, Donat SM, Herr HW, et al. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 2010;184:464–9.
   PubMed Web of Science ®Google Scholar
• de Reijke T, Kurth K, Sylvester R, Hall RR, Brausi M, van de Beek K, et al. Bacillus Calmette–Guérin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European organization for the research and treatment of cancer – genito-urinary group phase III trial (30906). J Urol 2005;173:405–9.
   PubMed Web of Science ®Google Scholar
• Jakse G, Hall R, Bono A, Höltl W, Carpentier P, Spaander J, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU group phase II protocol 30861. Eur Urol 2001;40:144–50.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro J, Martinez-Pineiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, et al. Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and TIS bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242–7.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124–9.
   PubMed Web of Science ®Google Scholar
• Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000;163:68–71.
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–72.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W Calais Da Silva F, EORTC Genito-Urinary Tract Cancer Group, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766–73.
   PubMed Web of Science ®Google Scholar
• Järvinen R, Kaasinen E, Rintala E, FinnBladder Group. Long-term results of mitomycin C versus alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective, randomized FinnBladder 2 study with a 17-year follow-up. Scand J Urol Nephrol 2012;46:411–17.
   PubMed Web of Science ®Google Scholar
• Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, FinnBladder Group, et al. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study. Eur Urol 2015;68:611–17.
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597–604.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003;170:777–82.
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43–51.
   PubMed Web of Science ®Google Scholar
• Andius P, Damm O, Holmäng S. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin. Scand J Urol Nephrol 2004;38:285–90.
   PubMed Web of Science ®Google Scholar
• Zieger K, Jensen K. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome. Scand J Urol Nephrol 2011;45:411–18.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62–7.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931–91.
   PubMed Web of Science ®Google Scholar
• Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 2014;66:694–701.
   PubMed Web of Science ®Google Scholar
• Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996;156:1286–7.
   PubMed Web of Science ®Google Scholar
• Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118–25.
   PubMed Web of Science ®Google Scholar